The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In one embodiment, the composition comprising a compound of formula I or salt...
Although siRNA holds promising prospects in drug development, several intracellular and extracellular barriers limit its extensive clinical application. Naked and unmodified siRNA possesses some disadvantages, such as (1) unsatisfactory stability and poor pharmacokinetic behavior and (2) the possible induction...
The term “parenteral” as used herein includes subcutaneous injections, aerosol, intravenous, intramuscular, intrathecal, intracranial injection, sub-lingual, lymphatically, or infusion or perfusion techniques. As used herein, a “pharmaceutically acceptable carrier” is a pharmaceutically acceptable solvent...
PGA conjugation of PTX also allowed for more rapid patient administration (10–20 min infusion compare to 3–24 h for free drug) and did not require premedication with corticosteroids and antihistamines due to the lower associated toxic side-effects [145]. Moreover, PGA-PTX prompted enhanced ...
Extended-infusion β-lactam therapy, mortality, and subsequent antibiotic resistance among hospitalized adults with Gram-negative bloodstream infections. JAMA Netw Open. 2024;7(7): e2418234. https://doi.org/10.1001/jamanetworkopen.2024.18234. Article PubMed PubMed Central Google Scholar Tran NN, ...
Teclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell–mediated cytotoxicity of multiple myeloma cells in preclinical studies. Objective A first-in-human, Phase I, dose escalation study (MajesTEC-1) is evaluating teclistamab in patients with rel...
The pharmaceutical compositions comprise from about 0.00002% to about 100%, especially, e.g., in the case of infusion dilutions that are ready for use) of 0.0001-0.02%, or, e.g., in case of injection or infusion concentrates or especially parenteral formulations, from about 0.1% to about...
The route of administration may vary and includes intravenous, intraperitoneal, sub-cutaneous, intramuscular, intranasal, via suppository, via infusion, via drip, orally or via other convenient means. The pharmaceutical composition may also comprise genetic molecules such as a vector capable of ...
pretreatment with antihistamines, nonsteroidal antihistamines or glucocorticoids was needed to reduce the incidence of infusion-related reactions. Phase 2 and 3 studies reached both the primary and second endpoints of the studies, according to the outcomes regarding the modified Neuropathy Impairment Score...
Here, radiopharmaceutical dosimetry exceeds expenses related to the infusion of chemotherapeutics (range, $478–1370). Cost estimates for managing hematologic or non-hematologic toxicities related to radiopharmaceutical administration have not been determined adequately to include in this article. However, ...